Urinary MRD Detection for Predicting Recurrence, Response to Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

Continuing his discussion at the AUA 2024 Annual Meeting, Vikram M. Narayan, MD, of Emory University School of Medicine, highlights the latest study on nadofaragene firadenovec.

This investigation looked at urinary minimal residual disease detection for predicting recurrence in BCG-unresponsive non-muscle invasive bladder cancer and for quantifying molecular response to the therapy.

View Dr. Narayan’s previous comments on 5-Year Follow-Up Data for Nadofaragene Firadenovec for BCG-Unresponsive NMIBC.